Sanara MedTech Q1 net revenue up 19% to $27.8M; GAAP EPS $0.04 vs ($0.07) loss

Sanara MedTech Inc.

2026-Q1 EPS reported $0.05 revenue$27,798,534

Net income from continuing ops of $0.4M ($0.04 diluted EPS) vs loss of $0.6M ($0.07) YoY.
Adjusted EBITDA $4.3M (+58% YoY); gross margin improved to 93% from 92%.
Soft tissue repair revenue rose 21% to $24.9M; bone fusion revenue essentially flat at $2.9M.
Q2 2026 revenue guidance $28.5M-$29.5M (10-14% growth); full-year 2026 reaffirmed at $116M-$121M.
Sales team expanded to 43 reps; products contracted at >4,000 U.S. facilities; cash $13.6M, debt $46.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sanara MedTech Inc. reported the first quarter ended March 31, 2026 results: revenue $27.8 million, net income $0.4 million, EPS $0.04 per diluted share.

Period: the first quarter ended March 31, 2026
Revenue: $27.8 million
Net income: $0.4 million
EPS: $0.04 per diluted share
Result: reported results

Exact text from the filing

in the surgical market, today reported its financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary (1) ● Net revenue increased 19% to $27.8 million, compared to $23.4 million in the first quarter of 2025. ● Gross profit of $25.9 million, or 93% of net revenue, compared to gross profit of $21.6 million, or 92% of net

View on SEC.gov

572 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-022291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.